3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Ovarian Cancer Recurrent
2
Multiple Myeloma
2
Melanoma
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Platinum-resistant Recurrent Ovarian Cancer
1
Platinum-resistant Ovarian Cancer
1
Peritoneal Neoplasms
1
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
1
Lymphoma, Follicular
1
Lymphoma
1
Esophageal Squamous Cell Carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumor
1
Advanced Malignancies
1
Adenoviridae Infections
1
Interventions
Rituximab
63
Cyclophosphamide
37
Brentuximab Vedotin
22
Bendamustine Hydrochloride
22
pembrolizumab
20
fludarabine
20
Gemcitabine
20
Doxorubicin
20
Prednisone
19
ibrutinib
17
Vincristine
16
obinutuzumab
14
Lenalidomide
13
Nivolumab
10
Rifampin
8
parsaclisib
7
duvelisib
7
atezolizumab
7
Vorinostat
7
Dexamethasone
7
Azacitidine
7
spartalizumab
6
loncastuximab tesirine
6
MLN 8237
6
venetoclax
5
ixazomib
5
glofitamab
5
fludarabine phosphate
5
durvalumab
5
acalabrutinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma
×
1-dodecylpyridoxal
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled